GSK and Bellus Health have entered into an agreement under which GSK will acquire Bellus, a Canada-based, late-stage biopharmaceutical company focused on treating refractory chronic cough (RCC) for approximately $2 billion (£1.6 billion). According to the company, the acquisition provides GSK access to camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC. P2X3 is a validated bi...